PMID- 37374110
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230701
IS  - 2075-1729 (Print)
IS  - 2075-1729 (Electronic)
IS  - 2075-1729 (Linking)
VI  - 13
IP  - 6
DP  - 2023 Jun 5
TI  - Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver 
      Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: 
      A Pilot Study.
LID - 10.3390/life13061327 [doi]
LID - 1327
AB  - Background: Both pemafibrate and sodium glucose cotransporter-2 (SGLT2) inhibitor 
      can decrease serum transaminase levels in patients with non-alcoholic fatty liver 
      disease (NAFLD) complicated with dyslipidemia and type 2 diabetes mellitus 
      (T2DM), respectively. However, the effectiveness of combined therapy has been 
      rarely reported. Methods: This is a two-center retrospective observational study. 
      NAFLD patients complicated with T2DM treated with pemafibrate for >1 year were 
      included, in whom prior treatment with SGLT2 inhibitor > 1 year failed to 
      normalize serum alanine aminotransferase (ALT) levels. Hepatic inflammation, 
      function, and fibrosis were assessed by ALT, albumin-bilirubin (ALBI) score, and 
      Mac-2 binding protein glycosylation isomer (M2BPGi) levels, respectively. 
      Results: Seven patients were included. The median duration of prior treatment 
      with SGLT2 inhibitors was 2.3 years. During the one year before starting 
      pemafibrate therapy, the therapy did not significantly change hepatic enzymes. 
      All patients received pemafibrate 0.1 mg twice daily without dose escalations. 
      During one year of pemafibrate therapy, triglyceride, aspartate aminotransferase, 
      ALT, gamma-glutamyl transpeptidase, ALBI score, and M2BPGi levels significantly 
      improved (p < 0.05), although weight or hemoglobin A1c did not significantly 
      change. Conclusions: One year of pemafibrate therapy improves markers of hepatic 
      inflammation, function, and fibrosis in NAFLD patients in whom long-term SGLT2 
      inhibitor therapy failed to normalize serum ALT.
FAU - Shinozaki, Satoshi
AU  - Shinozaki S
AUID- ORCID: 0000-0001-6935-4470
AD  - Shinozaki Medical Clinic, Utsunomiya 321-3223, Japan.
AD  - Department of Medicine, Division of Gastroenterology, Jichi Medical University, 
      Tochigi 329-0431, Japan.
FAU - Tahara, Toshiyuki
AU  - Tahara T
AD  - Saiseikai Utsunomiya Hospital, 911-1 Takebayashi, Utsunomiya 321-0974, Japan.
FAU - Miura, Kouichi
AU  - Miura K
AUID- ORCID: 0000-0001-8036-6544
AD  - Department of Medicine, Division of Gastroenterology, Jichi Medical University, 
      Tochigi 329-0431, Japan.
FAU - Lefor, Alan Kawarai
AU  - Lefor AK
AUID- ORCID: 0000-0001-6673-5630
AD  - Department of Surgery, Jichi Medical University, Tochigi 329-0431, Japan.
FAU - Yamamoto, Hironori
AU  - Yamamoto H
AD  - Department of Medicine, Division of Gastroenterology, Jichi Medical University, 
      Tochigi 329-0431, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230605
PL  - Switzerland
TA  - Life (Basel)
JT  - Life (Basel, Switzerland)
JID - 101580444
PMC - PMC10302975
OTO - NOTNLM
OT  - PPAR-alpha
OT  - dyslipidemias
OT  - non-alcoholic fatty liver disease
OT  - non-alcoholic steatohepatitis
OT  - pemafibrate
OT  - sodium glucose transporter-2 inhibitors
COIS- Authors S.S. and K.M. have received honoraria from Kowa Pharmaceuticals. Other 
      authors declare no conflict of interest. The funders had no role in the design of 
      the study; in the collection, analyses, or interpretation of data; in the writing 
      of the manuscript; or in the decision to publish the results.
EDAT- 2023/06/28 06:42
MHDA- 2023/06/28 06:43
PMCR- 2023/06/05
CRDT- 2023/06/28 01:24
PHST- 2023/04/12 00:00 [received]
PHST- 2023/06/02 00:00 [revised]
PHST- 2023/06/03 00:00 [accepted]
PHST- 2023/06/28 06:43 [medline]
PHST- 2023/06/28 06:42 [pubmed]
PHST- 2023/06/28 01:24 [entrez]
PHST- 2023/06/05 00:00 [pmc-release]
AID - life13061327 [pii]
AID - life-13-01327 [pii]
AID - 10.3390/life13061327 [doi]
PST - epublish
SO  - Life (Basel). 2023 Jun 5;13(6):1327. doi: 10.3390/life13061327.